Company news
Atlas Energy Corp. (TSXV:ATLE) news
Atlas Energy Corp. news releases on 6ix. Latest, Aug 29, 2023: Willow Bioscience shifts focus to opportunity with BioOxi bio-oxidation platform
Press releases — page 2
Willow Bioscience shifts focus to opportunity with BioOxi bio-oxidation platform
August 29, 2023
WILLOW BIOSCIENCES ANNOUNCES COMMERCIAL TRANSITION AND FOCUS ON BIOOXI PLATFORM
August 24, 2023
WILLOW ANNOUNCES COLLABORATION WITH A LEADING INNOVATIVE BIOPHARMACEUTICAL COMPANY TO DEVELOP SUSTAINABLE INTERMEDIATES AND ACTIVE PHARMACEUTICAL INGREDIENTS
August 21, 2023
WILLOW BIOSCIENCES REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS
August 8, 2023
WILLOW BIOSCIENCES TO PRESENT AT THE EMERGING GROWTH CONFERENCE ON AUGUST 9
August 2, 2023
WILLOW AND KALSEC ADVANCE DEVELOPMENT PROGRAM FOR NEW NATURAL FUNCTIONAL INGREDIENT FOR SAVORY FOODS
July 20, 2023
WILLOW BIOSCIENCES TO PRESENT AT THE EMERGING GROWTH CONFERENCE ON JUNE 14
June 7, 2023
Willow Bioscience agrees to partnership with biotech company looking at age-related diseases
June 2, 2023
WILLOW SIGNS MASTER SERVICES AGREEMENT WITH INNOVATIVE BIOTECH COMPANY TO DEVELOP INGREDIENTS FOR AGE-RELATED DISEASES
May 31, 2023
KALSEC AND WILLOW BIOSCIENCES TO DEVELOP NOVEL ENZYME FOR PRODUCTION OF AN ADVANCED BEVERAGE INGREDIENT
May 23, 2023
WILLOW BIOSCIENCES REPORTS FIRST QUARTER 2023 RESULTS
May 11, 2023
WILLOW ANNOUNCES COMMERCIAL AGREEMENT WITH SANDHILL ONE
April 18, 2023
WILLOW ANNOUNCES ROLLOUT OF BioOxi PLATFORM PROVIDING VALUABLE AND EXPEDITED BIOCONVERSION-ENABLED CHEMICAL MANUFACTURING
April 12, 2023
WILLOW BIOSCIENCES ANNOUNCES CHANGES TO BOARD AND MANAGEMENT
March 28, 2023
WILLOW & SUANFARMA ANNOUNCE COMPLETED DEVELOPMENT AND MANUFACTURING PROCESS FOR CBG AND COMMITMENT TO THE PRODUCTION OF NEW MOLECULES IN A NATURAL WAY
March 22, 2023
WILLOW BIOSCIENCES REPORTS FOURTH QUARTER AND FISCAL YEAR 2022 FINANCIALS AND OPERATIONS AND FILING OF ITS 2022 AIF
March 21, 2023
WILLOW ANNOUNCES APPOINTMENT OF DR. JIM LALONDE TO BOARD OF DIRECTORS
February 22, 2023
WILLOW ANNOUNCES FOLLOW-ON ENGAGEMENT FOR NEXT PHASE OF PARTNERED PHARMACEUTICAL PROJECT
January 17, 2023
WILLOW PROVIDES CORPORATE UPDATES, BUSINESS OUTLOOK AND KEY TARGETED MILESTONES ANTICIPATED FOR 2023 TO EXPAND GROWTH
December 14, 2022
WILLOW FURTHER OPTIMIZES ITS BUSINESS TO FOCUS ON NEAR-TERM REVENUE GENERATION AND REDUCE CASH BURN
December 7, 2022
KALSEC SIGNS MASTER SERVICES AGREEMENT WITH WILLOW BIOSCIENCES FOR THE DEVELOPMENT AND MANUFACTURE OF FUNCTIONAL FOOD INGREDIENTS USING PRECISION FERMENTATION
November 8, 2022
WILLOW BIOSCIENCES TO HOST INVESTOR PRESENTATION WEBCAST
November 7, 2022
WILLOW BIOSCIENCES REPORTS THIRD QUARTER 2022 RESULTS AND ANNOUNCES APPOINTMENT OF DR SEUFER-WASSERTHAL AS PRESIDENT AND CEO
November 3, 2022
WILLOW BIOSCIENCES ANNOUNCES NEW FUNCTIONAL INGREDIENT ASTAXANTHIN ADDED TO PRODUCT PORTFOLIO
October 12, 2022
WILLOW BIOSCIENCES PROVIDES CBG UPDATE
August 31, 2022
WILLOW BIOSCIENCES REPORTS SECOND QUARTER 2022 RESULTS
August 15, 2022
WILLOW BIOSCIENCES APPOINTS DR. PETER SEUFER-WASSERTHAL AS INTERIM PRESIDENT AND CEO
July 18, 2022
WILLOW BIOSCIENCES INCORPORATES INSCRIPTA'S ONYX® PLATFORM TO EXPAND STRAIN ENGINEERING CAPABILITIES AND THROUGHPUT
June 6, 2022
WILLOW BIOSCIENCES EXPANDS ITS PORTFOLIO WITH A NEW PARTNERED PHARMACEUTICAL PROJECT
May 31, 2022
WILLOW BIOSCIENCES ANNOUNCES ANNUAL GENERAL MEETING VOTING RESULTS
May 13, 2022
WILLOW BIOSCIENCES REPORTS FIRST QUARTER 2022 RESULTS
May 12, 2022
WILLOW BIOSCIENCES ANNOUNCES EXPANSION OF ITS FERMENTATION MANUFACTURING NETWORK AND PROGRESS ON ITS CBG GRAS DETERMINATION
May 11, 2022
WILLOW BIOSCIENCES REPORTS FOURTH QUARTER AND 2021 YEAR END RESULTS, FILING OF ITS 2021 AIF, AND OPERATIONAL UPDATE
March 29, 2022
WILLOW BIOSCIENCES PUBLISHES THE FIRST PEER REVIEWED ARTICLE DEMONSTRATING THE CLINICAL BENEFIT OF CBG FOR SKINCARE
January 19, 2022
Willow Biosciences Reports Third Quarter 2021 Results
November 15, 2021
Willow Biosciences Reports Second Quarter 2021 Results
August 9, 2021
Willow Biosciences Announces Expansion of its Commercial Operations Team and Development Portfolio, an Update on its Intellectual Property Position, and Formation of ESG Committee
July 20, 2021
Willow Biosciences and Cellular Goods Announce Multiyear Supply Agreement for Cannabigerol (CBG)
June 10, 2021
Willow Biosciences Announces Participation In Synbiobeta Panel Discussion
May 25, 2021
Willow Biosciences Added to NYSE-Listed Cannabis ETF "THCX"
May 18, 2021
Willow Biosciences Reports First Quarter 2021 Results, an Operational Update and the Addition of a New Board Member
May 7, 2021
Willow Biosciences Announces Ground-Breaking Scientific Data for Cannabigerol (CBG) on Human Skin
April 20, 2021
Willow Biosciences Announces Completion of its First Commercial Scale Fermentation Run
March 31, 2021
Willow Biosciences Reports Fourth Quarter and 2020 Year End Results and Operational Update
March 23, 2021
Willow Biosciences Provides Update on Acceleration of Expiry Date of Outstanding Warrants Issued Pursuant to October 2020 Unit Financing
March 3, 2021
Willow Biosciences Announces Exercise of Over-Allotment Option and Completion of Previously Announced Bought Deal Offering
February 19, 2021
IIROC Trade Resumption - WLLW
February 12, 2021
IIROC Trading Halt - WLLW
February 11, 2021
Willow Biosciences Announces Acceleration of Expiry Date of Outstanding Warrants Issued Pursuant to October 2020 Unit Financing
January 25, 2021
Willow Biosciences Advances Its Work On THC; Plans To Launch In The Canadian Market
January 19, 2021